10-K: Greater Cannabis Company Reports Annual Results for Fiscal Year 2024, Cites Going Concern Uncertainty

The Greater Cannabis Company reports $0 revenue for 2024 and expresses substantial doubt about its ability to continue as a going concern.

Summary

• The Greater Cannabis Company, Inc. reports its financial results for the year ended December 31, 2024.
• The company generated no revenue in 2024, consistent with 2023.
• Operating expenses amounted to $156,276 in 2024, compared to $175,364 in 2023.
• The net loss for 2024 was $179,041, slightly better than the $188,402 loss in 2023.
• The company had $57,368 in cash on hand at the end of 2024, a decrease from $166,859 at the end of 2023.
• The company has $171,437 in outstanding convertible notes, unchanged from the previous year.
• The report expresses substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative working capital.
• Management plans to secure additional funding sources to mitigate these concerns.

Sentiment

Score: 2

Explanation: The document indicates significant financial challenges, including no revenue, substantial losses, and concerns about the company's ability to continue as a going concern, resulting in a very negative sentiment.

Positives

• The net loss decreased slightly from 2023 to 2024.
• Operating expenses decreased from $175,364 in 2023 to $156,276 in 2024.

Negatives

• The company generated no revenue in 2024.
• The company has a significant accumulated deficit of $4,660,345.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• Cash reserves have decreased significantly.

Risks

• The company's ability to secure additional financing is uncertain.
• Government regulation of the marijuana industry poses a risk.
• The company faces risks related to environmental regulation and liability.
• The company faces risks related to tax assessments.
• The company acknowledges the risk that it will not be able to remediate identified material weaknesses in its internal control over financial reporting and disclosure controls and procedures.
• The company acknowledges the risk that it will be unable to secure additional financing in the near future in order to commence and sustain its planned development and growth plans.

Future Outlook

The company's future operating results, liquidity, and capital resources will be significantly affected by government regulation of the marijuana industry, revision of federal banking regulations, and legalization of marijuana in other states.

Industry Context

The company operates in the competitive cannabis space, with competitors ranging from cannabis producers to developers of cannabis delivery methods; known competitors include Jazz Pharmaceuticals and Zynerba Pharmaceuticals.

Legal Proceedings

• The company knows of no pending proceedings to which any director, member of senior management, or affiliate is either a party adverse to us or has a material interest adverse to us.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential cost-cutting measures or business cessation.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to allocate additional funds of approximately $250,000 from financing proceeds to research and development, sample productions and preclinical studies.
• The company intends to evaluate its processes and procedures and, where practicable and resources permit, implement changes in order to have more effective controls over financial reporting.

Key Dates

Keywords

cannabis, financial results, going concern, cannabinoid therapeutics, net loss, revenue, convertible notes, operating expenses